• Caris Molecular Intelligence Service examines the genetic and molecular makeup that is unique to each patient’s tumour. By comparing the tumour's information with data from clinical studies from thousands of the world's leading cancer researchers, Caris can help the physician determine which treatments are likely to be most effective and which treatments are likely to be ineffective for each patient. Caris Molecular Intelligence can be used to inform treatment selection when treating aggressive or rare tumors, or refractory disease. 

  • The Prosigna Breast Cancer Prognostic Gene Signature Assay is indicated in female breast cancer patients who have undergone surgery in conjunction with locoregional treatment consistent with standard of care, either as:

    • A prognostic indicator for distant recurrence-free survival at 10 years in post-menopausal women with Hormone Receptor- Positive (HR+), lymph node-negative, Stage I or II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors.
    • A prognostic indicator for distant recurrence-free survival at 10 years in post-menopausal women with Hormone Receptor-Positive (HR+), lymph node-positive (1–3 positive nodes), Stage II breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors. The device is not intended for patients with 4 or more positive nodes. 

  • Breakthrough genomic cancer testing from a single blood draw Guardant Health has helped thousands of oncologists learn accurate and actionable information about tens of thousands of patients, while avoiding the costs and risks of tissue biopsies. Guardant Health genomic test helps match advanced-cancer patients to approved targeted therapies as well as drugs in clinical trials.

    • Non-invasive
      A simple blood draw is all it takes
    • Comprehensive
      Our 70-gene panel targets actionable somatic alterations
    • Precise
      Our technology provides much greater sensitivity and specificity
    • Proven
      Used by most leading cancer centers and more than 1,000 clinics

  • Recent studies have shown that alterations in the BRCA1 and BRCA2 genes are responsible for the majority of hereditary breast and ovarian cancer. Such alterations increase the predisposition for breast and / or ovarian cancer and other cancers as well.

  • SelectMDx helps identify patients at increased risk for aggressive disease, thereby aiding in the selection of men for prostate biopsy. 
    SelectMDx provides the likelihood of detecting prostate cancer upon biopsy, and the probability for high-grade versus low-grade disease, with an area under the curve (AUC) of 0.89 (95% CI: 0.86-0.92).

    High Risk men may benefit from prostate biopsy and early detection.
    Low Risk men may avoid unnecessary invasive procedures with routine follow up and screening.